Tag: MedImmune
Successful Funding Round Expected to Accelerate ADC Therapeutics’ Clinical Development
Swiss Biotech company ADC Therapeutics, an oncology drug discovery and development company specializing in the development of proprietary antibody-drug conjugates or ADCs for the treatment...
Regeneron and MedImmune Sign Licensing Agreement for Pyrrolobenzodiazepine-based Payload and Linker...
This month Regeneron Pharmaceuticals, a science-based biopharmaceutical company based in Tarrytown, New York and MedImmune, the global biologics research and development arm of AstraZeneca entered...
London Calling: The Cutting-edge of Novel ADC Technologies
Major players in the rapidly advancing field of antibody drug conjugates (ADCs) will meet in London, United Kingdom, on 23-24 May for the annual...
MedImmune
MedImmune, the global biologics research and development arm of AstraZeneca, MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including...
Biparatopic HER2-targeting Antibody-drug Conjugate Demonstrates Potent Antitumor Activity
HER2-targeted therapies have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of breast cancer. Being overexposed in 20-25% of human breast cancers...
Companies Enter Into Strategic Collaboration and Licensing Agreement for the Development...
Earlier today, MedImmune, the lobal biologics research and development arm of AstraZeneca, and Tanabe Research Laboratories, a subsidiary of Mitsubishi Tanabe Pharma Corporation, a research-driven...
ADC Therapeutics Raises US$ 80 million to Advance ADC Pipeline
ADC Therapeutics, an oncology drug discovery and development company headquartered in Lausanne, Switzerland and London, UK, that specializes in the development of proprietary Antibody...
Strategic Immuno-Oncology Collaboration Between Celgene and MedImmune Focuses on Non-Hodgkin’s Lymphoma,...
Celgene, headquartered in Summit, New Jersey, and MedImmune (Gaithersburg, Maryland), a wholly owned subsidiary of AstraZeneca, have entered into a strategic collaboration to develop and...
ADCT-301 – A Novel Antibody-drug Conjugate Against Lymphomas – Moves Into...
ADC Therapeutics Sarl (Epalinges, Switzerland), a company involved in the development of antibody-drug conjugates against solid and hematological cancers, has filed an Investigational New Drug application or...
